Resumo

GARCIA-LUQUE, A; SILVA-CUEVAS, MA; GONZALO-SALADO, MH  e  GARCIA-SANCHEZ, S. Positive assessment of drugs: january, february and march of 2022. Sanid. Mil. [online]. 2022, vol.78, n.2, pp.101-105.  Epub 20-Jan-2023. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712022000200009.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public from January to March of 2022, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palavras-chave : Antígeno superficie del virus de la Hepatitis B (HbsAg), Pre-S1 Y Pre S2 (Prehevbri®); Ciltacabtagene Autoleucel (Carvykti®); Daridorexant (Quviviq®); Difelikefalin Acetato (Kapruvia®); Insulina Aspartat (Truvelog Mix 30®); Insulina Humana ADNr (Inpremzia®); Lisocabtagene Maraleucel (Breyanci®); Pegfilgrastim (Stimufend®); PF-07321332 / Ritonavir (Paxlovid®); Relugolix (Orgovyx®); Rimegepant (Vydura®); Tebentafusp (Kimmtrak®); Teriparatida (Sondelbay®); Tixagevimab / Cilgavimab (Evusheld®).

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )